Morgan Stanley Issues Positive Forecast for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its target price upped by investment analysts at Morgan Stanley from $175.00 to $190.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s price objective indicates a potential upside of 11.27% from the stock’s previous close.

Several other research firms have also recently issued reports on A. Bank of America raised their target price on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Royal Bank Of Canada upped their price target on Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. TD Cowen increased their price target on Agilent Technologies from $180.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus raised their price objective on Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Finally, Weiss Ratings raised Agilent Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.65.

Agilent Technologies Trading Down 0.3%

Shares of NYSE A traded down $0.58 during midday trading on Tuesday, reaching $170.75. 341,925 shares of the stock were exchanged, compared to its average volume of 2,260,540. The company has a 50 day simple moving average of $156.48 and a 200 day simple moving average of $136.00. The stock has a market capitalization of $48.14 billion, a P/E ratio of 33.61, a PEG ratio of 2.60 and a beta of 1.21. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $177.05.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The firm had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same quarter in the previous year, the company earned $1.37 EPS. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, equities analysts expect that Agilent Technologies will post 6.20 earnings per share for the current year.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $151.38, for a total value of $95,974.92. Following the sale, the director owned 4,924 shares of the company’s stock, valued at $745,395.12. The trade was a 11.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently modified their holdings of A. State Street Corp increased its stake in Agilent Technologies by 0.7% during the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company’s stock worth $1,710,658,000 after purchasing an additional 89,598 shares during the period. Wellington Management Group LLP lifted its position in shares of Agilent Technologies by 2.7% during the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after purchasing an additional 198,253 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Agilent Technologies by 17.1% in the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock valued at $930,957,000 after purchasing an additional 1,024,516 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after purchasing an additional 2,440,360 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Agilent Technologies by 9.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,108,764 shares of the medical research company’s stock valued at $240,336,000 after purchasing an additional 185,223 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.